Locoregional recurrence in studies of primary systemic therapy in early invasive breast cancer

A systematic literature review of studies of neoadjuvant systemic therapy identified that locoregional recurrence (LRR) was higher in patients under the age of 40, those who did not achieve a pathological complete remission, had ER-negative or HER2 negative tumours, were recorded to have inoperable disease at diagnosis, and did not have radiotherapy. LRR rates in these studies have not fallen over the overall calendar period of patient enrolment (1999–2016).

However, the recording of locoregional treatments and outcomes overall was suboptimal and efforts to improve this, particularly the PRECEDENT project are required.